Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease. - Casanova, M J; Chaparro, M; Nantes, O; Varela, P; Montserrat, R; Sierra, O G; Riestra, S; Barreiro-de Acosta, M; Martin-Rodriguez, M M; Gargallo-Puyuelo, C J; Reygosa, C; Munoz, R; et al. (Journal of Crohns & Colitis, 2022)